Dhiraj Kumar Chopra, Durga Madhab Kar, Pratap Kumar Sahu
Dhiraj Kumar Chopra*, Durga Madhab Kar, Pratap Kumar Sahu
School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Kalinga Nagar, Ghatikia, Bhubaneswar-751003, Orissa.
Volume - 13,
Issue - 5,
Year - 2020
The main aim of the current research work is to evaluate the potential of lipid based solid dispersions (OSD) to enhance oral bioavailability of Olmesartan Medoxomil (BCS Class II molecule). OSD have been prepared using different hydrophilic lipid based carriers such as gelucire 44/14 and gelucire 50/13 at the ratio of 1:1, 1:2 and 1:3. Pearlitol SD 200 was used as hydrophilic carrier in all the formulations to convert the lipid based solid dispersion to free flowing powder. Solid dispersions were prepared by solvent evaporation method. Prepared OSD’s were evaluated for their micromeritics properties, saturation solubility, in vitro dissolution and ex vivo permeability. Among the formulations prepared, formulation (OSD3) containing gelucire 44/14 (1:3), Pearlitol SD 200 as carrier has shown enhanced drug release (70.2 ± 6.5 release in 30 minutes) and solubility (44.32mg/mL) compared to other formulations. Hence, this formulation is evaluated for comparative ex vivo permeability with pure drug and marketed formulation (Olmezest). It was found that the permeability of OSD3 was increased compared to pure drug and compared to marketed formulation. Hence, the study demonstrated that lipid based solid dispersion technology can lead to improve the bioavailability of poorly soluble drugs like olmesartan medoxomil significantly.
Cite this article:
Dhiraj Kumar Chopra, Durga Madhab Kar, Pratap Kumar Sahu. Lipid based solid dispersions of Olmesartan medoxomil with Improved oral Bioavailability: In vitro and ex Vivo Evaluation. Research J. Pharm. and Tech 2020; 13(5):2096-2100. doi: 10.5958/0974-360X.2020.00377.7
1. M. Lindenberg, S. Kopp, J. B. Dressman. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. European Journal of Pharmaceutics and Biopharmaceutics 2004; 58: 265–278
2. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. European Journal of Pharmaceutical Sciences 2006; 29: 278–287.
3. Sucheta B, Dyandevi M, Mithun VKP Rajendra DP. Solubility enhancement of antihypertensive agent by solid dispersion technique. International Journal of Pharmacy and Life Sciences 2011; 2(8):970-975
4. Gaurav Subhash K, Bidkar SJ, Dama GY. Formulation & Evaluation of Ciprofloxacin Solid Dispersion Controlled Release Floating Capsules for Solubility Improvement. Indian Journal of Pharmaceutical and Biological Research 2017; 5(3):7-16.
5. Kumar MK, Kohli S, Jain AP. Evaluation of dissolution enhancement of lovaststin by solid dispersion technique. International Journal of Pharmacy and Life Sciences 2011; 2(7):894-898
6. Radhika Reddy P, Manjusha Reddy P Siva Koti Reddy A. Enhancement of bioavailability of Carbamazepine by solid dispersion technique. International journal of research in pharmacy and chemistry 2013; 3(1):54-56
7. Nadia S, Yeakuty M Naz Hasan H. Dissolution Profile of Ibuprofen Solid Dispersion Prepared with Cellulosic Polymers and Sugar by Fusion Method. Saudi Journal of Pharmaceutical Sciences 2011; 4(1): 31-37.
8. Bhandari KH, Newa M, Kim JA, Yoo BK, Woo JS, Lyoo WS, Lim HT, Choi HG, Yong CS. Preparation, characterization and evaluation of coenzyme Q10 binary solid dispersions for enhanced solubility and dissolution. Biological and Pharmaceutical Bulletin 2007; 30: 1171–1176.
9. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. International Journal of Pharmaceutics 2002; 231:131-144.
10. Huda NH, Saffoon N, Jhanker YM. Dissolution Enhancement of Ibuprofen Solid Dispersion Prepared with Vinyl Polymers by Fusion Method. Stamford Journal of Pharmaceutical Sciences 2010; 3(2): 7-11.
11. Laeis, P., Puchler, K., Kirch, W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. Journal of . Hypertension 2001; 19: 21-32
12. Nakagomi-Hagihara, R., Nakai, D., Kawai, K., Yoshigae, Y., Tokui, T., Abe, T., Ikeda, T. Oatp1b1, Oatp1b3 and Mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II Blocker. Drug Metabolism and Disposition 2006; 34: 862-869
13. Yamada, A., Maeda, K., Kamiyama, E., Sugiyama, D., Kondo, T., Shiroyanagi, Y., Nakazawa, H., Okano, T., Adachi, M., Schuetz, J. D., Adachi, Y., Hu, Z., Kusuhara, H., Sugiyama, Y. Multiple human isoforms of drug transporters contribute to the hepatic and renal transporter of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metaboilsm and Disposition 2007; 35: 2166-2176.
14. Chaitanyaprasad M, Vidyasagar G, Rao KR, Ramanjeneyulu S. Development of RP-HPLC method for estimation of olmesartan medoxomil in tablet dosage forms. Der Pharm Chem 2011;3:208-12
15. Yohan V, Syed M, Srinivasarao D. Research article on optimization of olmesartan tablet formulation by 2, 3 factorial design. International Journal of Research in Nanoscience 2015;4:188-95